Canada markets closed
  • S&P/TSX

    21,162.65
    +301.55 (+1.45%)
     
  • S&P 500

    4,686.75
    +95.08 (+2.07%)
     
  • DOW

    35,719.43
    +492.40 (+1.40%)
     
  • CAD/USD

    0.7912
    +0.0004 (+0.05%)
     
  • CRUDE OIL

    71.90
    -0.15 (-0.21%)
     
  • BTC-CAD

    63,503.02
    -1,242.66 (-1.92%)
     
  • CMC Crypto 200

    1,300.09
    -21.19 (-1.60%)
     
  • GOLD FUTURES

    1,788.90
    +4.20 (+0.24%)
     
  • RUSSELL 2000

    2,253.79
    +50.31 (+2.28%)
     
  • 10-Yr Bond

    1.4800
    +0.0460 (+3.21%)
     
  • NASDAQ futures

    16,400.25
    +82.25 (+0.50%)
     
  • VOLATILITY

    21.89
    -5.29 (-19.46%)
     
  • FTSE

    7,339.90
    +107.62 (+1.49%)
     
  • NIKKEI 225

    28,888.88
    +433.28 (+1.52%)
     
  • CAD/EUR

    0.7005
    -0.0009 (-0.13%)
     

SOPHiA GENETICS to Report Third Quarter 2021 Financial Results on November 10, 2021

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

BOSTON and LAUSANNE, Switzerland, Oct. 27, 2021 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq: SOPH) today announced it will report financial results for the third quarter of 2021 before market open on Wednesday, November 10, 2021. The company’s management will webcast a corresponding conference call beginning at 8:30 a.m. Eastern Time / 2:30 p.m. Central European Time to discuss its results, business developments, and outlook.

Live audio of the webcast will be available on the “Investors” section of the company website at ir.sophiagenetics.com. An archived replay will be available on the company’s website following the event.

About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform and related solutions, products and services are currently used by more than 780 hospital, laboratory, and biopharma institutions globally.

Media Contact:
Eliza Bamonti
ebamonti@sophiagenetics.com

Investor Contact:
ir@sophiagenetics.com


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting